Patents by Inventor Adam William Clarke
Adam William Clarke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220127352Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.Type: ApplicationFiled: January 5, 2022Publication date: April 28, 2022Inventors: David Jose Simon LAINE, Matthew POLLARD, Anthony Gerard DOYLE, Lynn Dorothy POULTON, Adam William CLARKE
-
Patent number: 11267883Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.Type: GrantFiled: December 21, 2017Date of Patent: March 8, 2022Assignee: Cephalon, Inc.Inventors: David Jose Simon Laine, Matthew Pollard, Anthony Gerard Doyle, Lynn Dorothy Poulton, Adam William Clarke
-
Publication number: 20200270339Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.Type: ApplicationFiled: December 21, 2017Publication date: August 27, 2020Inventors: David Jose Simon LAINE, Matthew POLLARD, Anthony Gerard DOYLE, Lynn Dorothy POULTON, Adam William CLARKE
-
Publication number: 20190106486Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: ApplicationFiled: October 18, 2018Publication date: April 11, 2019Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Patent number: 10138296Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: GrantFiled: September 16, 2016Date of Patent: November 27, 2018Assignee: Cephalon, Inc.Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Publication number: 20170081400Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: ApplicationFiled: September 16, 2016Publication date: March 23, 2017Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Publication number: 20160264661Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: April 22, 2016Publication date: September 15, 2016Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Hoi Yi Wai, Andrew James Pow, George Kopsidas
-
Patent number: 9127057Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: GrantFiled: July 20, 2011Date of Patent: September 8, 2015Assignee: Teva Pharmaceuticals Ausralia Pty LtdInventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Publication number: 20140086922Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: September 18, 2013Publication date: March 27, 2014Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Patent number: 8563697Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: GrantFiled: August 14, 2009Date of Patent: October 22, 2013Assignee: Cephalon Australia Pty. Ltd.Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Publication number: 20130115166Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: ApplicationFiled: July 20, 2011Publication date: May 9, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Publication number: 20110319597Abstract: The present invention relates to domain antibodies which have modified framework regions such that the potency or level of binding of the domain antibody is improved. In particular the present invention relates to domain antibodies which bind TNFa in which changes have been made to framework sequences and to constructs including these domain antibodies.Type: ApplicationFiled: August 13, 2009Publication date: December 29, 2011Applicant: Caphalon Australia Pty. Ltd.Inventors: Raina Jui Yu Simpson, Zehra Elgundi, Anthony Gerard Doyle, Philip Anthony Jennings, Robert Daniel Gay, Adam William Clarke
-
Publication number: 20110262445Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: August 14, 2009Publication date: October 27, 2011Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow